The immunogenicity of Mycobacterium paratuberculosis 85B antigen

Jacob Mullerad, Israel Michal, Yolanta Fishman, Avi Hai Hovav, Raul G Barletta, Herve Bercovier

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Mycobacterium paratuberculosis (MPT) is the etiological agent of paratuberculosis. The disease is prevalent throughout the world, and exacts a heavy financial toll. At present, the only means of controlling this disease are culling or vaccination. The existing vaccines are not very efficient and produce a long-lasting local reaction at the point of injection and induce anti- bodies/delayed-type hypersensitivity (DTH) reaction that cannot be differentiated from those of naturally infected animals. New potent acellular vaccines that allow discrimination between infected and vaccinated animals are necessary to improve the control of this disease. We have isolated, overexpressed and purified the 85B antigen of MPT, and characterized the immune response induced by this antigen in mice. Our results showed that the recombinant MPT 85B (rMPT 85B) antigen induced a high production of interferon (IFN)γ, interleukin (IL)-6, IL-10 and nitric oxide (NO). Spleen cells from mice immunized with rMPT 85B in Ribi adjuvant produced a higher level of IL-10 and NO than spleen cells of mice immunized with rMPT 85B only. In contrast, the addition of Ribi to the immunization protocol resulted in a lower amount of IFNγ released by spleen cells. The levels of spleen cells proliferation in mice vaccinated with the rMPT 85B protein alone or with rMPT 85B with Ribi adjuvant were, respectively, four times or five times greater than in the control mice. The Ribi adjuvant induced significantly higher anti-85B antibody production of all classes tested and increased the IgG1/IgG2a ratio. DTH responses in mice footpads were observed only in mice immunized with rMPT 85B emulsified in Ribi. rMPT 85B induced both a Th1 and Th2 type of immune response with the later slightly more pronounced when the vaccination protocol comprised Ribi as an adjuvant. The rMPT 85B antigen elicited a strong immune response and can be considered as a potential candidate for a future acellular vaccine.

Original languageEnglish (US)
Pages (from-to)179-187
Number of pages9
JournalMedical Microbiology and Immunology
Volume190
Issue number4
DOIs
StatePublished - Mar 26 2002

Fingerprint

Spleen
Acellular Vaccines
Delayed Hypersensitivity
Interleukin-10
Interferons
Nitric Oxide
Vaccination
Mycobacterium avium subsp. paratuberculosis
Paratuberculosis
Somatotypes
Histocompatibility Antigens Class II
Mycobacterium paratuberculosis antigen 85B
Antibody Formation
Anti-Idiotypic Antibodies
Immunization
Interleukin-6
Vaccines
Immunoglobulin G
Cell Proliferation
Antigens

Keywords

  • Antigen 85B
  • Mycobacterium paratuberculosis
  • Ribi adjuvant
  • Th1/Th2 immune response

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Microbiology (medical)

Cite this

The immunogenicity of Mycobacterium paratuberculosis 85B antigen. / Mullerad, Jacob; Michal, Israel; Fishman, Yolanta; Hovav, Avi Hai; Barletta, Raul G; Bercovier, Herve.

In: Medical Microbiology and Immunology, Vol. 190, No. 4, 26.03.2002, p. 179-187.

Research output: Contribution to journalArticle

Mullerad, J, Michal, I, Fishman, Y, Hovav, AH, Barletta, RG & Bercovier, H 2002, 'The immunogenicity of Mycobacterium paratuberculosis 85B antigen', Medical Microbiology and Immunology, vol. 190, no. 4, pp. 179-187. https://doi.org/10.1007/s00430-001-0104-z
Mullerad, Jacob ; Michal, Israel ; Fishman, Yolanta ; Hovav, Avi Hai ; Barletta, Raul G ; Bercovier, Herve. / The immunogenicity of Mycobacterium paratuberculosis 85B antigen. In: Medical Microbiology and Immunology. 2002 ; Vol. 190, No. 4. pp. 179-187.
@article{09eede1190c4458885ce3e2b6af00db7,
title = "The immunogenicity of Mycobacterium paratuberculosis 85B antigen",
abstract = "Mycobacterium paratuberculosis (MPT) is the etiological agent of paratuberculosis. The disease is prevalent throughout the world, and exacts a heavy financial toll. At present, the only means of controlling this disease are culling or vaccination. The existing vaccines are not very efficient and produce a long-lasting local reaction at the point of injection and induce anti- bodies/delayed-type hypersensitivity (DTH) reaction that cannot be differentiated from those of naturally infected animals. New potent acellular vaccines that allow discrimination between infected and vaccinated animals are necessary to improve the control of this disease. We have isolated, overexpressed and purified the 85B antigen of MPT, and characterized the immune response induced by this antigen in mice. Our results showed that the recombinant MPT 85B (rMPT 85B) antigen induced a high production of interferon (IFN)γ, interleukin (IL)-6, IL-10 and nitric oxide (NO). Spleen cells from mice immunized with rMPT 85B in Ribi adjuvant produced a higher level of IL-10 and NO than spleen cells of mice immunized with rMPT 85B only. In contrast, the addition of Ribi to the immunization protocol resulted in a lower amount of IFNγ released by spleen cells. The levels of spleen cells proliferation in mice vaccinated with the rMPT 85B protein alone or with rMPT 85B with Ribi adjuvant were, respectively, four times or five times greater than in the control mice. The Ribi adjuvant induced significantly higher anti-85B antibody production of all classes tested and increased the IgG1/IgG2a ratio. DTH responses in mice footpads were observed only in mice immunized with rMPT 85B emulsified in Ribi. rMPT 85B induced both a Th1 and Th2 type of immune response with the later slightly more pronounced when the vaccination protocol comprised Ribi as an adjuvant. The rMPT 85B antigen elicited a strong immune response and can be considered as a potential candidate for a future acellular vaccine.",
keywords = "Antigen 85B, Mycobacterium paratuberculosis, Ribi adjuvant, Th1/Th2 immune response",
author = "Jacob Mullerad and Israel Michal and Yolanta Fishman and Hovav, {Avi Hai} and Barletta, {Raul G} and Herve Bercovier",
year = "2002",
month = "3",
day = "26",
doi = "10.1007/s00430-001-0104-z",
language = "English (US)",
volume = "190",
pages = "179--187",
journal = "Medical Microbiology and Immunology",
issn = "0300-8584",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - The immunogenicity of Mycobacterium paratuberculosis 85B antigen

AU - Mullerad, Jacob

AU - Michal, Israel

AU - Fishman, Yolanta

AU - Hovav, Avi Hai

AU - Barletta, Raul G

AU - Bercovier, Herve

PY - 2002/3/26

Y1 - 2002/3/26

N2 - Mycobacterium paratuberculosis (MPT) is the etiological agent of paratuberculosis. The disease is prevalent throughout the world, and exacts a heavy financial toll. At present, the only means of controlling this disease are culling or vaccination. The existing vaccines are not very efficient and produce a long-lasting local reaction at the point of injection and induce anti- bodies/delayed-type hypersensitivity (DTH) reaction that cannot be differentiated from those of naturally infected animals. New potent acellular vaccines that allow discrimination between infected and vaccinated animals are necessary to improve the control of this disease. We have isolated, overexpressed and purified the 85B antigen of MPT, and characterized the immune response induced by this antigen in mice. Our results showed that the recombinant MPT 85B (rMPT 85B) antigen induced a high production of interferon (IFN)γ, interleukin (IL)-6, IL-10 and nitric oxide (NO). Spleen cells from mice immunized with rMPT 85B in Ribi adjuvant produced a higher level of IL-10 and NO than spleen cells of mice immunized with rMPT 85B only. In contrast, the addition of Ribi to the immunization protocol resulted in a lower amount of IFNγ released by spleen cells. The levels of spleen cells proliferation in mice vaccinated with the rMPT 85B protein alone or with rMPT 85B with Ribi adjuvant were, respectively, four times or five times greater than in the control mice. The Ribi adjuvant induced significantly higher anti-85B antibody production of all classes tested and increased the IgG1/IgG2a ratio. DTH responses in mice footpads were observed only in mice immunized with rMPT 85B emulsified in Ribi. rMPT 85B induced both a Th1 and Th2 type of immune response with the later slightly more pronounced when the vaccination protocol comprised Ribi as an adjuvant. The rMPT 85B antigen elicited a strong immune response and can be considered as a potential candidate for a future acellular vaccine.

AB - Mycobacterium paratuberculosis (MPT) is the etiological agent of paratuberculosis. The disease is prevalent throughout the world, and exacts a heavy financial toll. At present, the only means of controlling this disease are culling or vaccination. The existing vaccines are not very efficient and produce a long-lasting local reaction at the point of injection and induce anti- bodies/delayed-type hypersensitivity (DTH) reaction that cannot be differentiated from those of naturally infected animals. New potent acellular vaccines that allow discrimination between infected and vaccinated animals are necessary to improve the control of this disease. We have isolated, overexpressed and purified the 85B antigen of MPT, and characterized the immune response induced by this antigen in mice. Our results showed that the recombinant MPT 85B (rMPT 85B) antigen induced a high production of interferon (IFN)γ, interleukin (IL)-6, IL-10 and nitric oxide (NO). Spleen cells from mice immunized with rMPT 85B in Ribi adjuvant produced a higher level of IL-10 and NO than spleen cells of mice immunized with rMPT 85B only. In contrast, the addition of Ribi to the immunization protocol resulted in a lower amount of IFNγ released by spleen cells. The levels of spleen cells proliferation in mice vaccinated with the rMPT 85B protein alone or with rMPT 85B with Ribi adjuvant were, respectively, four times or five times greater than in the control mice. The Ribi adjuvant induced significantly higher anti-85B antibody production of all classes tested and increased the IgG1/IgG2a ratio. DTH responses in mice footpads were observed only in mice immunized with rMPT 85B emulsified in Ribi. rMPT 85B induced both a Th1 and Th2 type of immune response with the later slightly more pronounced when the vaccination protocol comprised Ribi as an adjuvant. The rMPT 85B antigen elicited a strong immune response and can be considered as a potential candidate for a future acellular vaccine.

KW - Antigen 85B

KW - Mycobacterium paratuberculosis

KW - Ribi adjuvant

KW - Th1/Th2 immune response

UR - http://www.scopus.com/inward/record.url?scp=0036124403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036124403&partnerID=8YFLogxK

U2 - 10.1007/s00430-001-0104-z

DO - 10.1007/s00430-001-0104-z

M3 - Article

C2 - 12005331

AN - SCOPUS:0036124403

VL - 190

SP - 179

EP - 187

JO - Medical Microbiology and Immunology

JF - Medical Microbiology and Immunology

SN - 0300-8584

IS - 4

ER -